Discover investment opportunities in AI Biotech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in AI Biotech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in AI Biotech Stocks using our Smart AI Filter.
6 stocks found for "AI Biotech Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.34 Risk measure | ±55.5% Price volatility | -10.4 Valuation | 0.00% Annual yield | |||
1.72 Risk measure | ±55.7% Price volatility | 68.8 Valuation | 0.00% Annual yield | |||
1.21 Risk measure | ±61.6% Price volatility | -8.4 Valuation | 0.00% Annual yield | |||
0.61 Risk measure | ±31.4% Price volatility | 19.2 Valuation | 0.00% Annual yield | |||
1.57 Risk measure | ±95.0% Price volatility | -3.0 Valuation | 0.00% Annual yield | |||
0.85 Risk measure | ±64.0% Price volatility | -5.8 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How does Illumina's (ILMN) role in the AI-driven biotechnology sector enhance its investment appeal?
A: Illumina (ILMN) is a leader in genetic sequencing technologies, crucial for AI applications in biosciences. Investors may find appeal in its strategic partnerships and investments in AI to advance precision medicine, potentially driving innovation and market leadership.
Q: What potential growth factors should investors consider for CRISPR Therapeutics (CRSP)?
A: Investors may consider CRISPR Therapeutics' (CRSP) pioneering role in gene-editing technology, which holds transformative healthcare potential. Collaboration with major pharmaceutical companies and its diverse R&D pipeline may further drive growth prospects.
Q: How does Ginkgo Bioworks (DNA) leverage AI in its business model?
A: Ginkgo Bioworks (DNA) uses AI-driven synthetic biology to engineer microorganisms for various industries. Its platform's efficiency, bolstered by AI, may attract investors interested in innovative R&D and broad commercial applications.
Q: What risks are associated with investing in Beam Therapeutics (BEAM)?
A: Beam Therapeutics (BEAM) involves high-risk as its base editing technology remains largely experimental. Regulatory hurdles and the need for continued research funding pose significant investment risks.
Q: How does Intellia Therapeutics (NTLA) differentiate itself within the biotech sector?
A: Intellia Therapeutics (NTLA) differentiates through its in vivo CRISPR genome editing, catering to unmet medical needs. Strategic collaborations and advancements in proprietary technology offer competitive advantages in the biotech landscape.
Q: What makes Editas Medicine (EDIT) a potential opportunity for biotech investors?
A: Editas Medicine (EDIT) focuses on CRISPR-based gene editing solutions aimed at treating genetic disorders. Its potential lies in early-phase clinical trials and collaborations, which might appeal to investors seeking innovative biotherapeutic businesses.